



Capacity building to support the uptake of biosimilars in a multistakeholder approach (HADEA/2023/OP/0040)

In the first year, AUGMENT will analyse biosimilar policies and practices in Europe and summarise results in a study report and dashboard to be published.

The AUGMENT Consortium was commissioned by the European Health and Digital Executive Agency (HaDEA) to conduct the project "Capacity building to support the uptake of biosimilars in a **multistakeholder approach**" from July 2024 until July 2027.

The **overall aim** of the project is the support of national authorities in implementing policies and practices that improve biosimilar competition, as a means to contribute to the accessibility, affordability and availability of medicines for patients in the EU.




- Improving biosimilars knowledge & awareness across European countries
- Building capacity of public authorities in implementing and optimising biosimilar policies
- Engaging with stakeholders to capture their expertise and perspectives



Year 1: **Study** on biosimilar policies & **dashboard**

Year 2: **Workshops** and **study visits** to countries

Year 3: **Tailored roadmaps** and **training itineraries**



Please note: This document was produced in the frame of the HADEA/2023/OP/0040 contract. The information and views set out in this document are those of the author(s) and do not necessarily reflect the official opinion of the Commission/Executive Agency. Neither the Commission/Executive Agency nor any person acting on the Commission's/Executive Agency's behalf may be held responsible for the use which may be made of the information contained therein.

Please cite as: Vogler S., Habimana K., Schneider P., Knoll V., Helder T. (2024): Onepager for 'Capacity building to support the uptake of biosimilars in a multistakeholder approach'. Gesundheit Österreich Forschungs- und Planungs GmbH.

Available here: [Home | WHOCC PPRI \(goeg.at\)](https://www.whoocp.org)